California-based biopharmaceutical firm, Aimunne Therapeutics has been notified that due to the government shutdown, the US Food and Drug Administration (FDA) will not review the company’s Biologics License Application (BLA) for its investigational peanut
We saw a major milestone in FDA approvals in 2018, but a political deadlock that led to a partial government shutdown before Christmas could take some of the shine off a golden year.....